PMV Pharmaceuticals, Inc..
PMVP.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
PMV Pharmaceuticals, Inc. is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies that selectively target p53, a tumor suppressor protein. Their approach focuses on restoring p53 activity in cancer cells, thereby inhibiting tumor growth an...Show More
Better Health for All
-10
PMV Pharmaceuticals is a precision oncology company entirely focused on developing small molecule therapies targeting p53 mutations in cancer.
1
Its lead product candidate, rezatapopt, is in Phase 2 clinical trials for advanced solid tumors, showing an overall response rate (ORR) of 34% across 103 evaluable patients and 46% in the ovarian cancer cohort.
2
The company plans to submit a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer in early 2027.
3
The company's business model since inception has been focused on maximizing health benefits, with no evidence of harmful products. However, the company expects to price its product candidates at a significant premium over competitive generic products if approved.
4
In terms of safety, rezatapopt was generally well-tolerated across 112 patients, with most treatment-related adverse events (TRAEs) being Grade 1-2.
5
Rates of individual Grade 3 TRAEs were ≤6%, and drug discontinuations due to a TRAE were 3.6%.
6
Notable adverse events included one Grade 4 and six Grade 3 liver enzyme elevations (ALT) among 109 patients.
7
The company's R&D expenses increased to $17.4 million in Q1 2025 from $13.2 million in Q1 2024.
8
The company is subject to data privacy and security laws, including GDPR and HIPAA, and includes a detailed 'Risk Factors' section in its Form 10-K.
9
Clinical trials are conducted under protocols, with informed consent from all research subjects, and are reviewed and approved by an independent IRB or ethics committee for each site.
10
Fair Money & Economic Opportunity
0
No evidence available to assess PMV Pharmaceuticals, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
40
PMV Pharma reported zero health and safety-related incidents in 2023.
1
The company maintained a voluntary employee turnover rate of 6% as of 2023.
2
PMV Pharma offers competitive medical coverage to its workforce.
3
Fair Trade & Ethical Sourcing
0
The provided articles do not contain sufficient specific, quantitative evidence to score PMV Pharmaceuticals, Inc. against the 'Fair Trade & Ethical Sourcing' value. While some articles mention the existence of a Vendor Code of Conduct and expectations for suppliers regarding labor practices, anti-corruption, and environmental compliance,
1
they do not provide concrete data points such as percentages of certified spend, audit frequencies, numbers of incidents, traceability coverage, remediation speeds, or supplier diversity spend.
2
Therefore, no KPIs can be scored based on the available information.
Honest & Fair Business
0
PMV Pharmaceuticals reported zero health and safety-related incidents in 2023 and no regulatory fines in the past three years.
1
The company maintains a confidential, independent web portal and hotline available 24 hours a day, seven days a week for reporting needs, and explicitly prohibits retaliation against anyone who makes a report in good faith.
2
No financial restatements have been mentioned in the past five years.
3
The company maintains a Global Anti-Bribery and Anti-Corruption Policy.
4
Five out of seven board members are independent, which is approximately 71.4%.
5
For third-party verification, the company tracks and disposes of hazardous waste through a third-party vendor, and collaborates with external contract organizations for animal testing studies accredited by organizations such as AAALAC.
6
Qualification audits are conducted for vendors performing critical GXP functions.
7
Kind to Animals
0
PMV Pharmaceuticals conducts pre-clinical studies of its drugs on animals to assess product safety.
1
The company does not conduct animal testing within its own facilities, instead collaborating with external contract organizations for these studies.
2
Its animal welfare policy, adopted in April 2022, states that all animal research, whether by the company or a vendor, is conducted in accordance with industry and government standards to ensure appropriate care for the animals.
3
PMV ensures that these contracted efficacy and safety studies involving animals are accredited with organizations such as the American Association for Accreditation of Laboratory Animal Care (AAALAC).
4
No War, No Weapons
0
No specific, concrete data points or relevant information regarding PMV Pharmaceuticals, Inc.'s association with arms manufacturing, military contracts, conflict facilitation, or peace initiatives were found in the provided article.
1
Therefore, no KPIs could be scored against the 'No War, No Weapons' value.
Planet-Friendly Business
0
The provided articles offer no specific quantitative data points that can be mapped to the 'Planet-Friendly Business' KPIs. While some reports mention general commitments to sustainability, the use of SASB and UN SDGs,
1
and the implementation of energy efficiency measures like LED lighting and recycling programs, these are descriptive actions rather than measurable metrics such as total greenhouse gas emissions, renewable energy percentages, water usage, or waste diversion rates. There is also no evidence of science-based targets, lifecycle impact analyses, or details on climate-related policies or investments. Multiple articles explicitly state a lack of information on regulatory actions, violations, fines, or compliance issues,
2
which means there is no concrete data to score against that KPI.
Respect for Cultures & Communities
0
The provided articles focus exclusively on PMV Pharmaceuticals' research and development efforts related to mutant p53 cancer therapies and its oncology pipeline.
1
No data or information relevant to the company's engagement with cultures and communities, including partnerships, community investments, cultural impact assessments, local employment, or grievance mechanisms, is present in the articles for the 'Respect for Cultures & Communities' value.
2
Safe & Smart Tech
0
No evidence available to assess PMV Pharmaceuticals, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No quantitative data, regulatory actions, violations, fines, certifications, awards, recognitions, industry benchmarks, or comparisons to peers were found in the provided articles regarding PMVP.US's Zero Waste & Sustainable Products initiatives.
1
The articles explicitly state that the content is introductory placeholder text and does not contain any relevant data for the specified metrics.
2